Answers are grounded in this paper and cite their sources.
BACKGROUND: The 17-item Hamilton Depression Rating Scale (HAM-D 17) remains the 'gold standard' for measuring treatment outcomes in clinical trials of depressed patients. The Montgomery Asberg Depression Rating Scale (MADRS), Clinical Global Impressions-Severity (CGI-S) and -Improvement (CGI-I) scales are also widely used. OBJECTIVE: This analysis of data from 22 double-blind, placebo-controlled clinical studies of venlafaxine in adult patients with major depressive disorder was aimed at assessing correlations among these 4 scales. METHODS: Changes from baseline for MADRS, HAM-D 17 and CGI-S, and end point CGI-I scores and response (>or=50% decrease from baseline HAM-D 17 or MADRS, or CGI-S or CGI-I score <or=2) were analysed. Pearson correlation coefficients were calculated for all pairs of the four scales (HAM-D 17/MADRS, HAM-D 17/CGI-S, HAM-D 17/CGI-I, MADRS/CGI-S, MADRS/CGI-I, CGI-S/CGI-I) at different time points. Effect sizes were calculated using the Cohen d. RESULTS: Correlations were significant at all time points (p < 0.0001), increased over the course of treatment, and were similar across treatment groups. Effect sizes ranged from 0.31 to 0.42; MADRS and CGI-I effect sizes were slightly greater compared with HAM-D 17 or CGI-S for continuous measures and response. CONCLUSION: Although MADRS and CGI-I were more sensitive to treatment effects, HAM-D 17, MADRS, CGI-S and CGI-I scores present a consistent picture of response to venlafaxine treatment.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: